Studies: Inflammation-Targeting Antibody Boosts Preterm Birth Outcomes, Prevents Obesity-Linked Liver Disease

Targeting a master regulator of inflammation with a monoclonal antibody potentially improves two unrelated conditions with limited treatment options: preterm births and fatty liver disease, two new studies show.

Mounting research makes it clear that runaway inflammation drives the severity of a broad array of diseases and conditions, said Joe G.N. “Skip” Garcia, M.D., associate vice president for research at UF Health. In preterm birth related to uterine infection and in nonalcoholic fatty liver disease related to obesity, inflammatory signals go haywire, igniting significant disease and worsening outcomes, the studies show.

Read more about Studies: Inflammation-Targeting Antibody Boosts Preterm Birth Outcomes, Prevents Obesity-Linked Liver Disease.